Orexigen Announces Publication Of Contrave Real-World Study Results In "Obesity" /PRNewswire/ -- Orexigen Therapeutics, Inc. today announced that results of its IGNITE study were published online by Obesity , the peer-reviewed journal of The Obesity Society . The IGNITE study was an open-label randomized Phase 3b study designed to evaluate the use of ContraveA in combination with a commercially-available comprehensive lifestyle intervention program compared with usual care in a real-world weight-loss setting.
Specifically, we have targeted high-prescribing healthcare practitioners across the U.S., and two weeks ago, we launched a broad and compelling patient activation campaign across the range of traditional and digital media," said , President and Chief Executive Officer of Orexigen. "In addition to these key U.S. initiatives, we have made significant progress in building a global network of distribution and selling partners with strong local and regional relationships.
Health Consequences of Prolonged Smoking to Aid Steady Growth of Smoking Cessation and Nicotine De-Addiction Products Market, Says TMR Smoking cessation or nicotine de-addiction can be achieved by various modes such as nicotine replacement products, e-cigarettes, anti-depressants and nicotine receptor agonists such as Zyban , and Chantix/Champix . Quitting smoking is also possible with or without assistance of healthcare professionals.